Oruka Therapeutics, Inc. - COMMON STOCK (ORKA)

CUSIP: 687604108

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 6 signals
Share change
+744,317
SEC-reported price per share
$10.26
Indexed holders
70
Value change
-$21,453,560
Number of buys
43
Number of sells
22
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
66,547,970

Security key

687604108

Report period

Q1 2025

Indexed institutions

70

Top holders

10

Ownership snapshot

Top reported holders of ORKA - Oruka Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Venrock Healthcare Capita...
Disclosed value leader
Fairmount Funds Managemen...
Comparable rows
0/15
Latest evidence
10 Feb 2025
3/4/5 13F Highest disclosed value: $65,381,568 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Fairmount Funds Management LLC has the largest disclosed position value at $65.38M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Fairmount Funds Management LLC's linked filing trail.
Disclosed position value Top 5
Venrock Healthcare Capital Partne... $47.46M
Funicular Funds, LP $22.9M
Janus Henderson Group Ltd. $16.41M
Fairmount Funds Management LLC $65.38M
Venrock Adviser, LLC $63.71M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Venrock Healthcare Capital Partners III, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$47,458,016
4,148,428 shares
— 10 Feb 2025
Funicular Funds, LP
3/4/5
Other*, 10%+ Owner
—
mixed-class rows
$22,903,390
9,179,356 shares
mixed-class rows
— 15 Dec 2022
Janus Henderson Group Ltd.
13F 3/4/5
Company · 10%+ Owner
—
denominator unverified
$16,414,848
849,410 shares
— 31 Dec 2024
Fairmount Funds Management LLC
13F
Company
13F
—
denominator unverified
$65,381,568
3,371,922 shares
— 31 Dec 2024
Venrock Adviser, LLC
13F
Company
13F
—
denominator unverified
$63,708,172
3,285,620 shares
— 31 Dec 2024
RTW INVESTMENTS, LP
13F
Company
13F
—
denominator unverified
$37,726,134
1,945,649 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
70
Shares
31,776,517
Indexed holders
70
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 indexed holders
66
Q1 2025 indexed holders
70
Indexed holder difference
4
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 value Q1 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .